Objective  To investigate the clinical efficacy and safety of Xuefu Zhuyu oral liquid (XZOL) on patients with lupus nephritis (LN) and the effect of serum thymosin β4.

Methods  Patients treated in the Second Hospital Affiliated to Hebei North College from October 2021 to October 2022 were included in the study. Using the random number method, the LN patients were divided into the control group [prednisone (PDN)+cyclophosphamide (CTX)] and the blood-focused group (XZOL combined with PDN+CTX), and were treated continuously for 6 months. The two groups were compared in terms of treatment efficiency, systemic lupus erythematosus disease activity index (SLEDAI) score, immune indexes [anti-double-stranded DNA (dsDNA) antibody, serum immunoglobulin (Ig)G and serum complement C3 levels] and renal function indexes (Scr, ALB, ESR, ALT, 24h urine protein and CRP levels), serum thymidine β4 levels and safety (incidence of adverse reactions).

Results  A total of 60 LN patients were included in the study, 30 in each group. The total effective rate of treatment in the Xuefu Zhuyu group was significantly higher than that in the control group (P<0.05). Before treatment, there was no statistically significant difference in SLEDAI score, serum thymidine β4, IgG, C3, anti-dsDNA antibody, serum Scr, ALB, ALT, 24 h urine protein and CRP levels between the two groups (P>0.05). After 6 months of treatment, SLEDAI score, serum IgG, anti-dsDNA antibody, serum Scr, ALT, 24 h urine protein and CRP levels of patients in both groups decreased significantly compared with those before treatment (P<0.05), while serum thymosin β4 level, serum C3 level and serum ALB level increased significantly (P<0.05); the SSLEDAI score, serum IgG, anti-dsDNA antibody, serum Scr, ALT, 24 h urine protein and CRP levels were lower in the Xuefu Zhuyu group than in the control group (P<0.05), and serum thymosin β4, C3 and ALB levels were higher than in the control group (P<0.05). In addition, there was no difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion  XZOL is clinically effective in the treatment of LN, with fewer adverse reactions, and is worth promoting its use in the clinic.

1.莫玉兰, 吴玮, 黎兆军, 等. 以皮肤水疱和狼疮肾炎为首发症状的大疱性系统性红斑狼疮1例[J]. 中国皮肤性病学杂志, 2021, 35(7): 780-784. [Mo YL, Wu W, Li ZJ, et al. A case of bullous systemic lupus erythematosus with skin blisters and lupus nephritis as the initial symptoms[J]. Chinese Journal of Dermatology and Venereology, 2021, 35(7): 780-784.] DOI: 10.13735/j. cjdv.1001-7089.202101122.

2.江坚青. 益肾活血法治疗狼疮性肾炎的Meta分析[D]. 南昌: 江西中医药大学, 2023.

3.曾嵘, 李瑞哲, 付怡雯, 等. 狼疮性肾炎临床指南和共识的方法学质量评价[J]. 中国循证医学杂志, 2022, 22(1): 103-110. [Zeng R, Li RZ, Fu YW, et al. Methodological quality evaluation of clinical guidelines and consensus for lupus nephritis[J]. Chinese Journal of Evidence Based Medicine, 2022, 22(1): 103-110.] DOI：10.7507/1672-2531.202108144.

4.Gasparotto M, Gatto M, Binda V, et al. Lupus nephritis: clinical presentations and outcomes in the 21st century[J]. Rheumatology (Oxford), 2020, 59 (Suppl5): v39-v51. DOI: 10.1093/rheumatology/keaa381.

5.Li D, Pan B, Ma N, et al. Efficacy and safety of Shenqi Dihuang decoction for lupus nephritis: a systematic review and meta-analysis[J]. J Ethnopharmacol, 2024, 323: 117602. DOI: 10.1016/j. jep.2023.117602.

6.Wang YJ, Li YX, Li S, et al. Progress in traditional Chinese medicine and natural extracts for the treatment of lupus nephritis[J]. Biomed Pharmacother, 2022, 149: 112799. DOI: 10.1016/j.biopha.2022.112799.

7.李小丽, 夏玉红, 陈亚飞, 等. 胸腺肽联合辛伐他汀治疗哮喘-慢阻肺重叠综合征老年患者临床观察[J]. 内科, 2021, 16(6): 761-764, 839. [Li XL, Xia YH, Chen YF, et al. Clinical observation of thymic peptide combined with simvastatin in the treatment of elderly patients with asthma COPD overlap syndrome[J]. Internal Medicine, 2021, 16(6): 761-764, 839.] DOI: 10.16121/j.cnki.cn45-1347/r.2021.06.14.

8.张少君, 林洁琼, 曾洪武. 儿童胸腺平扫CT密度与细胞免疫功能关系的初步研究[J]. 临床放射学杂志, 2022, 41(10): 1952-1955. [Zhang SJ, Lin JQ, Zeng HW. A preliminary study on the relationship between CT density and cellular immune function in children's thymus plain scan[J]. Journal of Clinical Radiology, 2022, 41(10): 1952-1955.] DOI: 10.13437/j.cnki.jcr.2022.10.016.

9.麦迪, 贺镜宇, 贾祎鹏, 等. 沙利度胺联合胸腺肽对系统性红斑狼疮患者免疫功能及Th1/Th2平衡的影响[J]. 中国医学创新, 2022, 19(33): 55-60. [Mai D, He JY, Jia YP, et al. The effect of thalidomide combined with thymosin on immune function and Th1/Th2balance in patients with systemic lupus erythematosus[J]. Chinese Medical Innovation, 2022, 19(33): 55-60.] DOI: 10.3969/j. issn.1674-4985.2022.33.013.

10.李淑欢. 胸腺肽辅助治疗难治性狼疮性肾炎的临床观察[D]. 上海: 上海交通大学, 2016.

11.曾惠芬, 刘芳, 缪蕙, 等. 胸腺肽肠溶片联合甲氨蝶呤治疗类风湿性关节炎的疗效[J]. 实用中西医结合临床, 2018, 18(7): 134-136. [Zeng HF, Liu F, Miao H, et al. The efficacy of thymic peptide enteric coated tablets combined with methotrexate in the treatment of rheumatoid arthritis[J]. Practical Clinical Practice of Integrated Traditional Chinese and Western Medicine, 2018, 18(7): 134-136.] DOI: 10.13638/j.issn.1671-4040.2018.07.072.

12.郭琼芳, 汪汉东, 张李刚, 等. 加减参芪地黄汤联合泼尼松片对狼疮性肾炎肾功能的影响[J]. 中华医院感染学杂志, 2020, 30(13): 2000-2004. [Guo QF, Wang HD, Zhang LG, et al. The effect of modified Shenqi Dihuang decoction combined with prednisone tablets on renal function in lupus nephritis[J]. Chinese Journal of Hospital Infection, 2020, 30(13): 2000-2004.] DOI: 10.11816/cn. ni.2020-191847.

13.刘枚, 潘文友, 孟德钎,等. 昆仙胶囊联合糖皮质激素治疗狼疮性肾炎的临床研究[J]. 中国中西医结合杂志, 2020, 40(8): 919-922. [Liu M, Pan WY, Meng DZ, et al. Clinical study of Kunxian capsules combined with glucocorticoids in the treatment of lupus nephritis[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine, 2020, 40(8): 919-922.] DOI: 10.7661/j. cjim.20200627.074.

14.苏保林, 陈刚毅, 汤水福. 真武汤联合免疫抑制剂治疗脾肾阳虚型狼疮性肾炎的疗效观察[J]. 中华中医药杂志, 2019, 34(2): 858-861. [Su BL, Chen GY, Tang SF. Observation on the therapeutic effect of Zhenwu Tang combined with immunosuppressive agents in the treatment of lupus nephritis with spleen kidney yang deficiency type[J]. Chinese Journal of Traditional Chinese Medicine, 2019, 34(2): 858-861.] DOI: CNKI:SUN:BXYY.0.2019- 02-114.

15.杨兆方, 申斌. 血府逐瘀汤加减治疗慢性肾炎临床研究总结资料[J]. 世界最新医学信息文摘, 2017, 17(84): 103, 136. [Yang ZF, Shen B. Summary of clinical research on the treatment of chronic nephritis with modified Xuefu Zhuyu Tang[J]. World's Latest Medical Information Digest, 2017, 17(84): 103, 136.] DOI: 10.19613/j. cnki.1671-3141.2017.84.081.

16.司蕾, 潘月丽. 血府逐瘀汤加减治疗小儿紫癜性肾炎验案举隅[J]. 世界最新医学信息文摘, 2017, 17(45): 166. [Si L, Pan YL. A case study of modified Xuefu Zhuyu Tang in the treatment of pediatric purpura nephritis[J]. World's Latest Medical Information Digest, 2017, 17(45): 166.] DOI: 10.3969/j. issn.1671-3141.2017.45.092.

17.黄国东, 马晓露, 石宏斌, 等. 血府逐瘀口服液对育龄期女性狼疮性肾炎患者性激素水平的调节作用研究[C]. 第六次全国中西医结合血瘀证及活血化瘀研究学术大会, 2024.

18.陈闯嘉宝, 黄秉洲, 邓李霜, 等. 胸腺肽的免疫调节活性及其在病毒性疾病中的应用[J]. 畜牧与兽医, 2023, 55(11): 138-144. [Chen CJB, Huang BZ, Deng LS, et al. The immunomodulatory activity of thymosin and its application in viral diseases[J]. Livestock and Veterinary Medicine, 2023, 55(11): 138-144.] https://www.zhangqiaokeyan.com/academic-journal-cn_detail_thesis/02012102702158.html.

19.Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. Kidney Int, 2004, 65(2): 521-530. DOI: 10.1111/j.1523-1755.2004.00443.x.

20.中华医学会风湿病学分会. 系统性红斑狼疮诊断及治疗指南中华医学会风湿病学分会[J]. 中华风湿病学杂志, 2010, 14(5): 342-346. DOI: 10.3760/cma.j.issn.1007- 7480.2010.05.016.

21.Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000[J]. The Journal of rheumatology, 2002, 29(2): 288-291. DOI: 10.1097/00124743-200202000-00018.

22.邱小辉, 林承春, 王林娣. 胸腺肽联合恩替卡韦治疗乙肝肝硬化的疗效及对患者肝功能、炎症指标水平的影响[J]. 中外医疗, 2022, 41(35): 159-162, 167. [Qiu XH, Lin CC, Wang LD. Efficacy of thymosin combined with entecavir in the treatment of hepatitis B cirrhosis and its influence on liver function and inflammatory index level of patients[J]. Chinese and Foreign Medical, 2022, 41(35): 159-162, 167.] DOI: 10.16662/j. cnki.1674-0742.2022.35.159.